BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results
BRTXBioRestorative Therapies(BRTX) Newsfilter·2024-06-17 19:05
  • Significant YoY improvement in operating performance - - Ends Q1-2024 with $16.4 million cash, cash equivalents, and marketable securities - MELVILLE, N.Y., June 17, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, announced that it has received notice from the Nasdaq Stock Market that it has regained compliance with Nasdaq Listing Rule 5250(c)(1) in connection with the filing o ...